Radiopharm Theranostics Ltd ADR(RADX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:02 PM ET (Korea 10/31 05:02)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.17 | Insider Own | - | Shs Outstand | 11.8M | Perf Week | 6.93% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 3.42% | Insider Trans | - | Shs Float | - | Perf Month | -27.03% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 1.81% | Short Float | - | Perf Quarter | -65.27% |
| Income | -0.04B | P/S | 9.02 | EPS this Y | 43.31% | Inst Trans | -94.62% | Short Ratio | 2.49 | Perf Half Y | -75.51% |
| Sales | 0.00B | P/B | 0.75 | EPS next 5Y | - | ROA | -76.21% | Short Interest | 0.14M | Perf YTD | -79.31% |
| Book/sh | 1.45 | P/C | 5.91 | EPS past 3/5Y | 44.7% -56.2% | ROE | -161.31% | 52W High | -93.35% ($16.25) | Perf Year | -79.11% |
| Cash/sh | 0.18 | P/FCF | - | Sales past 3/5Y | 112.06% - | ROIC | -219.08% | 52W Low | 20% ($0.90) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 8.58% | Gross Margin | -87.9% | Volatility(W/M) | 10.71% 15.9% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 6.62 | Sales Y/Y TTM | -19.76% | Oper. Margin | -2476.13% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.16 | EPS Q/Q | -15.85% | Profit Margin | -1994.08% | RSI (14) | 40.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.16 | Sales Q/Q | -31.95% | SMA20 | 1.34% ($1.07) | Beta | 1.27 | Target Price | $12.75 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/28 | SMA50 | -31.73% ($1.58) | Rel Volume | 0.16 | Prev Close | $1.12 |
| Employees | 14 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -49.01% 48.59% | SMA200 | -70.68% ($3.68) | Avg Volume(3M) | 0.06M | Price | $1.08 |
| IPO | 2024/12/5 | Option/Short | No/Yes | Trades | 67 | Volume | 8,923 | Change | -3.26% |
☢️ An innovative clinical-stage biotech company developing diagnostic and therapeutic radiopharmaceuticals for precision cancer treatment.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
RADX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +43.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $902. Peers typically go for $1,089.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.8%.
Tap to view numbers
It ranks #470 of 595 in the industry
Based on market cap of $17M.
MCRB#467 Seres Therapeutics Inc $18M PER - 
CNTX#468 Context Therapeutics Inc $17M PER - 
JSPR#469 Jasper Therapeutics Inc $17M PER - RADX#470 Radiopharm Theranostics Ltd ADR $17M PER - 
NEUP#471 Neuphoria Therapeutics Inc $17M PER - 
FAQ
What kind of company is RADX?
RADX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RADX?
The market cap of RADX is approximately $17M, ranking 5,256 within its sector.
What is the 52-week high and low for RADX?
RADX has recorded a 52-week high of $16.25 and a low of $0.90.
